IL315322A - Lyophilized formulations of aav drug products - Google Patents

Lyophilized formulations of aav drug products

Info

Publication number
IL315322A
IL315322A IL315322A IL31532224A IL315322A IL 315322 A IL315322 A IL 315322A IL 315322 A IL315322 A IL 315322A IL 31532224 A IL31532224 A IL 31532224A IL 315322 A IL315322 A IL 315322A
Authority
IL
Israel
Prior art keywords
adeno
frozen
associated virus
drug product
product formulations
Prior art date
Application number
IL315322A
Other languages
English (en)
Hebrew (he)
Inventor
Dingjiang Liu
Li Zhi
Yao Chen
Kuan-Yu Lai
Jonathan Wert
Xiaoyan Wang
Original Assignee
Regeneron Pharma
Dingjiang Liu
Li Zhi
Yao Chen
Lai Kuan Yu
Jonathan Wert
Xiaoyan Wang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Dingjiang Liu, Li Zhi, Yao Chen, Lai Kuan Yu, Jonathan Wert, Xiaoyan Wang filed Critical Regeneron Pharma
Publication of IL315322A publication Critical patent/IL315322A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL315322A 2022-03-14 2023-03-13 Lyophilized formulations of aav drug products IL315322A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263319657P 2022-03-14 2022-03-14
PCT/US2023/015112 WO2023177626A1 (en) 2022-03-14 2023-03-13 Lyophilized formulations of aav drug products

Publications (1)

Publication Number Publication Date
IL315322A true IL315322A (en) 2024-10-01

Family

ID=85979703

Family Applications (1)

Application Number Title Priority Date Filing Date
IL315322A IL315322A (en) 2022-03-14 2023-03-13 Lyophilized formulations of aav drug products

Country Status (11)

Country Link
US (1) US20230293724A1 (https=)
EP (1) EP4493162A1 (https=)
JP (1) JP2025509566A (https=)
KR (1) KR20250002229A (https=)
CN (1) CN119072302A (https=)
AR (1) AR128785A1 (https=)
AU (1) AU2023233503A1 (https=)
CA (1) CA3245651A1 (https=)
IL (1) IL315322A (https=)
TW (1) TW202406560A (https=)
WO (1) WO2023177626A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025076729A1 (zh) * 2023-10-11 2025-04-17 朗信启昇(苏州)生物制药有限公司 包含aav的药物组合物及其制备方法
WO2025114524A1 (en) * 2023-11-30 2025-06-05 Uniqure Biopharma B.V. Formulations for viral drug products
WO2025185606A1 (en) * 2024-03-04 2025-09-12 Nanjing Legend Biotech Co., Ltd. Composition for cryoprotection of viral vector or vlp
WO2025188316A1 (en) * 2024-03-08 2025-09-12 Jaguar Gene Therapy, Llc Aav pharmaceutical formulations and methods thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021009370A2 (pt) * 2018-11-14 2021-08-17 Regenxbio Inc. método de tratamento da doença de batten cln2, composição farmacêutica e kit
SG11202107645RA (en) * 2019-01-18 2021-08-30 Voyager Therapeutics Inc Methods and systems for producing aav particles
TW202332458A (zh) * 2019-04-19 2023-08-16 美商銳進科斯生物股份有限公司 腺相關病毒載體調配物及方法
WO2021071835A1 (en) * 2019-10-07 2021-04-15 Regenxbio Inc. Adeno-associated virus vector pharmaceutical composition and methods
TW202144575A (zh) * 2020-04-03 2021-12-01 美商拜奧馬林製藥公司 使用aav及治療調配物之苯酮尿症治療

Also Published As

Publication number Publication date
US20230293724A1 (en) 2023-09-21
TW202406560A (zh) 2024-02-16
JP2025509566A (ja) 2025-04-11
EP4493162A1 (en) 2025-01-22
AR128785A1 (es) 2024-06-12
AU2023233503A1 (en) 2024-09-19
KR20250002229A (ko) 2025-01-07
CA3245651A1 (en) 2023-09-21
WO2023177626A1 (en) 2023-09-21
CN119072302A (zh) 2024-12-03

Similar Documents

Publication Publication Date Title
IL315322A (en) Lyophilized formulations of aav drug products
EP4045480A4 (en) PHARMACEUTICAL FORMULATIONS
IL288204A (en) Protein-targeted compounds and their pharmaceutical preparations and their medical applications
IL283134A (en) Alcohol-resistant drug formulations
DK3935068T3 (da) Abirateron-prodrugs
IL285674A (en) Pharmaceutical formulations
EP4221690A4 (en) PHARMACEUTICAL COMPOSITIONS
IL285147A (en) Dry pharmaceutical formulations of cnp conjugates
ES2850277R1 (es) Composiciones de administración farmacéutica y usos de las mismas
EP3906019C0 (en) Pharmaceutical compositions of furosemide
EP3897593A4 (en) CANNABINOID FORMULATIONS AND PHARMACEUTICAL COMPOSITIONS
EP4135699A4 (en) Pharmaceutical compositions
DK3981390T3 (da) Farmaceutisk lacosamid-sammensætning og farmaceutisk præparat deraf
EP3599892C0 (en) CHEWABLE GEL PRODUCTS FOR PHARMACEUTICAL ACTIVE INGREDIENTS
EP3946316A4 (en) PHARMACEUTICAL CANNABIDIOL COMPOSITIONS
EP3914234A4 (en) Pharmaceutical compositions
IL285421A (en) Indazolyl-isoxazole derivatives, their preparation and pharmaceutical compositions containing them
EP3746080A4 (en) PHARMACEUTICAL FORMULATIONS
EP3868371A4 (en) Novel pharmaceutical composition
DK3908321T3 (da) Farmaceutisk sammensætning
IL291351A (en) Compositions for the treatment of solid tumors
DK4027973T3 (da) Formuleringer til lægemiddeladministration
CR20220587A (es) Formulaciones farmacéuticas
PL3787596T3 (pl) Ulepszone formulacje farmaceutyczne
PT3949952T (pt) Composição farmacêutica